BREAKWATER Supports FDA Approval of Encorafenib-Cetuximab-FOLFIRI for BRAF V600E-Mutant mCRC
Encarnafenib plus cetuximab with FOLFIRI significantly improves progression‑free and overall survival compared with FOLFIRI ± bevacizumab as first‑line therapy in patients with BRAF V600E‑mutant metastatic colorectal cancer.
This phase 3 randomized trial demonstrated that encorafenib plus cetuximab with FOLFIRI improves progression‑free and overall survival versus FOLFIRI ± bevacizumab in first‑line treatment of BRAF V600E‑mutant metastatic colorectal cancer.
These findings support FDA approval, offering a more effective first‑line therapy for a subset of metastatic colorectal cancer patients with limited treatment options.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics